Clinical Trials
2 trialsNCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT06784648 2025-11-19
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
Phase 1/2 Active not recruiting